Skip to main content

Table 3 Change after 1 year MK-4 supplementation

From: Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study

CAC

 

N

Pre

1 year

Difference

%Difference

Paired P value

Baseline P value

Total

 

26

513 ± 773

588 ± 872

72 ± 143

+14 %

0.018

 

PIVKA2

23

22

421 ± 543

481 ± 610

60 ± 132

+14 %

0.052

0.64

PIVKA2

>23

4

1010 ± 1558

1151 ± 1761

141 ± 204

+14 %

0.26

 

ucOC

<4.5

19

348 ± 448

402 ± 515

55 ± 139

+16 %

0.11

0.38

ucOC

4.5

7

947 ± 1232

1064 ± 1387

117 ± 157

+12 %

0.09

 

PWV

 

N

Pre

1 year

Difference

 

Paired P value

Baseline P value

Total

 

26

1834 ± 289

1821 ± 378

−12.7 ± 263

−0.7 %

0.811

 

PIVKA2

23

22

1826 ± 280

1872 ± 379

47 ± 226

+2.6 %

0.34

0.79

PIVKA2

>23

4

1882 ± 379

1542 ± 248

−340 ± 164

−18 %

0.026

 

ucOC

<4.5

19

1859 ± 293

1882 ± 410

22 ± 261

+1.2 %

0.71

0.26

ucOC

4.5

7

1766 ± 288

1659 ± 220

−107 ± 240

−6.1 %

0.28

 
  1. Despite 1 year MK-4 supplementation, CAC increased +14 % annually. High PIVKA2 and high ucOC indicate vitamin K insufficiency at baseline. Those with high PIVKA2 had significant reduction of PWV